TCR αβ-depleted hematopoietic stem cell transplant and third-party CD45RA+ depleted adoptive cell therapy for treatment of post-transplant parvovirus B19 aplastic crisis
CD19 and CD22-targeted chimeric antigen receptor (CAR) T-cell therapy bridged to hematopoietic stem cell transplantation (HSCT) has emerged as an effective therapeutic approach for refractory/relapsed acute lymphoblastic leukemia [1,2]. However, despite successful therapy, patients remain vulnerable to viral infections caused by prolonged immune system deficiency. Human parvovirus (HPV) B19 infection is among the frequently encountered viral infections post-transplantation. Effective treatment for persistent HPV B19 infection in immunocompromised patients has yet to be established.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Manpin Zhang, Chengjuan Luo, Jianmin Wang, Hua Zhu, Changying Luo, Xia Qin, Xiaohang Huang, Yuchen Lin, Jing Chen Tags: Case Report Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Erythema Infectiosum | Infectious Diseases | Leukemia | Parvovirus | Stem Cell Therapy | Stem Cells | Transplants